EBITDA: Income before interest, taxes, depreciation and amortization.
Greenwich LifeSciences, Inc. (GLSI) had EBITDA of $-5.73M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-5.66M |
|
-- |
|
-- |
|
$5.73M |
|
$-5.73M |
|
$0.07M |
|
$-5.66M |
|
$-5.66M |
|
$-5.66M |
|
$-5.66M |
|
$-5.66M |
|
$-5.66M |
|
$-5.73M |
|
|
EBITDA |
$-5.73M |
14.56M |
|
14.56M |
|
$-0.39 |
|
$-0.39 |
|
| Balance Sheet Financials | |
$10.51M |
|
-- |
|
-- |
|
$10.51M |
|
$5.24M |
|
-- |
|
-- |
|
$5.24M |
|
$5.27M |
|
$5.27M |
|
$5.27M |
|
14.67M |
|
| Cash Flow Statement Financials | |
$-4.70M |
|
-- |
|
$9.03M |
|
$6.18M |
|
$10.51M |
|
$4.33M |
|
$1.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.70M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-107.34% |
|
-107.34% |
|
-53.85% |
|
-107.34% |
|
$0.36 |
|
$-0.32 |
|
$-0.32 |
|